The effects of purified soluble fibrin and of fibrinogen fragments (fibrin mimic) on the activation of Lysplasminogen (i.e. plasminogen residues 77-790) to plasmin by streptokinase -plasminogen activator complex and by tissue-type plasminogen activator were studied. Dissociation constants of both activators were estimated to lie in the range 90-160 nm (fibrin) and 16-60 nM (CNBr-cleavage fragments of fibrinogen). The kinetic mechanism for both types of activator comprised non-essential enzyme activation via a Rapid Equilibrium Ordered Bireactant sequence. In order to relate the fibrin affinity of pIasminogen activators to their fibrinolytic potency, the rate of lysis of supported human plasma clots formed in the presence of unmodified or active-centre-acylated precursors of plasminogen activators was studied as a function of the concentration of enzyme derivative. The concentrations of unmodified enzyme giving 50 % lysis/h in this assay were 0.9, 2.0 and 11.0 nm for tissue-type plasminogen activator, streptokinase-plasmin(ogen) and urokinase respectively. However, the potencies of active-centre-acylated derivatives of these enzymes suggested that acylated-tissue plasminogen activator and streptokinase * plasminogen complexes of comparable hydrolytic stability were of comparable potency. Both types of acyl-enzyme were significantly more potent than acyl-urokinases.
INTRODUCTION
The binding to fibrin of the components of the fibrinolytic system forms an essential part of any model of selective physiological fibrinolysis (Wiman & Collen, 1978; Collen, 1980) . The interaction of plasminogen with fibrin has been the subject of many studies and the affinity of different plasminogen forms for various types of fibrin has been reported (Suenson & Thorsen, 1981; Lucas et al., 1983; Bok & Mangel, 1985) . Dissociation constants (K) for Glu-plasminogen of 24-42 /iM were found, whereas those for Lys-plasminogen ranged from 0.32 to 7.9 guM. Plasminogen activators, which are trypsinlike serine proteinases catalysing the cleavage of the Arg-560-Val-561 bond in human plasminogen, may undergo several types of interaction with fibrin, the nature and strength of which may influence the performance of such enzymes as thrombolytic agents. Hoylaerts et al. (1982) estimated a Kr for tissue-type plasminogen activator (t-PA) binding to formed polymeric fibrin 20-160 nM according to whether Lys-plasminogen or Glu-plasminogen was present to form a ternary complex with t-PA and fibrin. A similar study based on the kinetics of plasminogen activation by urokinase (u-PA) in the presence of CNBr-cleavage fragments of fibrinogen suggested that u-PA underwent much weaker interactions with fibrin-related structures . Although the complexing of streptokinase with plasminogen has been reported to increase the affinity of the latter protein for fibrin (Cederholm-Williams, 1981) , a quantitative comparison of the binding of the streptokinase-plasminogen complex (SK-Plg) and t-PA in the presence of excess plasminogen has not been made. Kinetic and thrombus-binding studies in this laboratory with the acyl-enzyme p-anisoyl-plasminogen-streptokinase complex (BRL 26921, APSAC; Smith et al., 1981) have suggested that the undegraded SK * Plg complex can bind to fibrin with an affinity that may be of significance for the clinical use of this fibrinolytic pro-drug (Fears et al., 1985a,b) . We therefore undertook the -present comparison of SK -Plg and t-PA using a fibrin interaction assay based upon fibrin stimulation of plasminogen activation in a purified system. We then compared the potencies of free and active-centre-acylated forms of these enzymes, together with u-PA, in a clot-lysis assay in vitro. These comparisons were aimed at clarifying the relationship between the affinity for fibrin and the lytic potency of plasminogen activators with therapeutic potential.
MATERIALS AND METHODS Materials
Human two-chain urokinase (Mr 54000; specific activity 100000 units/mg; urinary origin) was obtained from Serono (Freiburg, W. Germany). Recombinant tissue-type plasminogen activator was purified to homoAbbreviations used: Glu-plasminogen, human plasminogen with N-terminal glutamic acid (residues 1-790); Lys-plasminogen, human plasminogen with N-terminal lysine (residues 77-790); SK, streptokinase; SK.Plg, streptokinase complexed with human Lys-plasminogen; u-PA, urinary-type plasminogen activator; t-PA, tissue-type plasminogen activator; PAGE, polyacrylamide-gel electrophoresis; PDAEB, 
geneity from the culture supernatant of a genetically manipulated human cell line (Browne et al., 1985) and had M, 63 000 by SDS/PAGE/fibrin-overlay autography (Granelli-Piperno & Reich, 1978) . Human thrombin (1000 NIH units/mg of protein) was obtained from Sigma Chemical Co. (Poole, Dorset, U.K.). l25l-fibrinogen was a product of Amersham International (Amersham, Bucks., U.K.) and was repurified as described previously . 4-Anisoyl-Lys-plasminogen-streptokinase complex (BRL 26921) was prepared as described elsewhere (Smith et al., 1982) . Active-siteacylated derivatives of u-PA and t-PA were prepared by treating the activators (6-9/,M) in 0.05 M-sodium phosphate buffer, pH 7.4, containing 0.1 M-NaCl and 0.01 % Tween 80 with the appropriate 4-amidinophenyl esters (1.0 mM) at 25°C for 60 min. Acyl-enzymes were freed of excess acylating agent by gel filtration into the same buffer on small Sephadex G-25 columns (Pharmacia, Milton Keynes, Bucks., U.K.). Acyl-enzymes were stored in solution for short periods at -70 'C. Deacylation rate constants were determined as described previously (Smith et al., 1985) . The preparation of CNBr-cleavage fragments of fibrinogen was adapted from the procedure of Verheijen et at. (1982) as follows.
Human fibrinogen (grade L; Kabivitrum, Stockholm, Sweden) (1.0 g) was treated with CNBr (1.3 g) in 70 % (v/v) formic acid (100 ml) at 18°C for 17 h. Unused CNBr and formic acid were removed by dialysis against deionized water for 24 h and the product was freezedried. Analysis by SDS/PAGE (10 % separating gel) in non-reducing conditions disclosed six protein-stainable degradation products at apparent Mr values 88000, 70000, 38000, 36000 and two less than 20000. The total yield of fragments was 90 %. Fragments were dissolved in 0.05 M-NaOH to give a stock solution of 30 mg/ml, which was then diluted to 5 mg/ml with 0.05 M-Tris/HCl buffer, pH 7.4, containing 0.1 M-NaCl. Small portions were stored at -40 'C at which temperature plasminogen-activation-enhancing activity was stable (R. Fears & R. Standring, unpublished work) . The sources of other materials and the preparation of soluble fibrin oligomers have been described previously (Fears et al., 1985b) . Active-site titration
The operational molarity of t-PA and u-PA was determined by active-site titration with the chromogenic inverse substrate 4-anisic acid 4'-amidino-2'-nitrophenyl ester (Smith et al., 1985; Smith, 1986) . This compound reacts with the enzymes, releasing 4-amidino-2-nitrophenol which has 6405 5028 M-1 cm-' in 20 mM-Tris/HCl buffer, pH 7.4, containing 0.5 M-L-arginine, 0.5 M-NaCl and 0.01 % Tween 80 at 25 'C. SK -Plg was titrated with 4-nitrophenyl 4'-guanidinobenzoate during complexformation (Chase & Shaw, 1967; McClintock & Bell, 1971 ).
Plasminogen activation
The method was the same as that described previously (Fears et al., 1985b) except that t-PA was diluted with the phosphate buffer described above. The concentration of activator added was 0.3 nm for t-PA and 0.1 nm for streptokinase. Kinetic constants were averages of quadruplicate determinations for a range of concentrations of Lys-plasminogen (0.2-10 x Km for SK and 0.2-5 x Km for t-PA) and enhancing protein (0.01-0.5 /sM).
In previous studies the assay had been found to be reproducible. For example, with t-PA the basal Km was estimated to be 17.5 + 1.5 #M (n = 5), which decreased to 0.044 + 0.003 uM in the presence of a digested fibrin clot (Fears et al., 1985b) , and the basal Km for streptokinase was 0.33 + 0.07 #M (n = 5), decreasing to 0.036 + 0.008 ItM.
Clot-lysis assay
Enzymes or acyl-enzymes were diluted from stock solutions into ice-cold portions (0.6 ml) ofpooled citrated human plasma (fibrinogen content 7.3 sM) containing 6 kBq of 1251-human fibrinogen/ml. For each enzyme concentration, groups of five deactivated micro-fibreglass filter discs (1.0 cm, type GF/D; Whatman, Maidstone, Kent, U.K.) were treated with human thrombin (10 1 of 100 NIH units/ml in 0.05 M-sodium phosphate buffer, pH 7.4, containing 0.1 M-NaCl, 0.01 % Tween 80 and 10 mg of human serum albumin/ml) followed by plasma containing the agent (0.1 ml). The plasma was allowed to clot for 10 min at ambient temperature (20-24°C) and the discs were then washed by gentle rotation in phosphate/albumin buffer (20 ml at 4°C for 15 min). The discs were squeezed free of buffer with forceps and transferred to vials, and the 1251 content was determined by y-radiation counting (Bioscint; Panax, Ruislip, Middx., U.K.). They were added to unlabelled unsupplemented human plasma (0.9 ml) and incubated at 37 "C for 1 h.
Discs were freed of adhering plasma by squeezing with forceps and the residual 1251 content was determined. With each set of determinations (three to five concentrations), a control group of five discs with no enzyme added to the labelled plasma was included.
Data processing
Lysis-rate data were fitted to a general form of the Langmuir Adsorption Isotherm {lysis 
RESULTS AND DISCUSSION Plasminogen activation
For the activation of Lys-plasminogen by streptokinase (as the activator complex with plasminogen formed in situ), the decrease in Km (fibrin enhancement) was proportional to the concentration of soluble fibrin present (Fig. la) . Vmax was unaffected and the requirement for fibrin disappeared when the substrate concentration was high. If the experimental data were replotted as the reciprocals of initial velocity and fibrin concentration (Fig. lb) , the fibrin dissociation constant could be determined (Table 1) . Results from the double-reciprocal plots were consistent with a kinetic mechanism involving non-essential enzyme activation via a Rapid Equilibrium Ordered Bireactant sequence, and the competitive activation by fibrin is one means of distinguishing this mechanism from Rapid Equilibrium Random and Steady State Ordered reactions (Segal, 1975) . Although Km can be determined from the limiting plot in Fig. 1(a) , it was more practical to calculate Km also provided confirmation of the value for K, (Table 1) .
Another method of deriving Kf is shown in Fig. l(a) inset. This yielded a value of 125 nm (Table 1) . Fig. 1(b) inset shows that the slope of the double-reciprocal plot (Fig. lb) activity (Hoylaerts et al., 1982) and for the moderate stimulation of streptokinase activity by intact fibrinogen or fibrinogen fragment (Chibber et al., 1985) . We have shown previously (Fears et al., 1985b) (Chibber et al., 1985) that there is more than one conformational arrangement of the streptokinase plasminogen activator complex and that only an early species can be stimulated, at least by fibrinogen. It should be noted that, unless the active centre within the plasminogen moiety of the complex is inactivated by acylation, proteolytic cleavage within the streptokinase component occurs (Brockway & Castellino, 1974; Markus et al., 1976) . It is likely, at least initially, that the deacylated form of APSAC/BRL 26921 (which is prepared by acylative trapping of the nascent streptokinase * plasminogen complex) will be intact SK* Plg, responsive to fibrin stimulation.
The use of soluble fibrin in this and previous studies (Fears et al., 1985b) permitted kinetic investigations that were not possible with solid-phase fibrin. However, the quantification and characterization of such preparations is laborious, the preparations cannot be stored for reasonable periods and it proved difficult to obtain reproducible products with different batches offibrinogen and thrombin. The soluble cofactor, CNBr-digested fibrinogen, has also been found to be useful as a fibrin mimic in kinetic studies with t-PA (Zamarron et al., 1984) ; we have also used this cofactor in the study of streptokinase.
The activation of Lys-plasminogen by SK-Plg was enhanced by the CNBr-cleavage fibrinogen fragment (Hoylaerts et al., 1982; Zamarron et al., 1984; Fears et al, 1985b) , the Km of t-PA for plasminogen activation was markedly decreased by both soluble fibrin and by CNBr-cleavage fibrinogen fragments ( urokinase has a very large K, and a small second-order rate constant in the presence of fibrin: 70 tM-1 min-' (R. Fears, unpublished work).
Clot lysis
The clot-lysis system used in this study consisted of a small (100 ,ul) human plasma clot induced by addition of citrated plasma containing 1251-labelled human fibrinogen and the fibrinolytic enzyme to a filter-disc support impregnated with human thrombin. After clotting, serum and unbound enzyme were removed by washing at 4°C and the lysis rate was measured radiochemically during subsequent incubation at 37°C in citrated human plasma containing no fibrinolytic agent. By incorporating the fibrinolytic enzymes into forming fibrin, diffusion barriers to exogenous lytic agents were eliminated.
The dependence of lysis rate upon the concentrations of both unmodified enzymes and their acyl derivatives was found to be sigmoidal in form and could be fitted by computerized non-linear-regression analysis to the generalized form of the Langmuir Adsorption Isotherm ( Van den Brink, 1977 native SK. [Glu1]Plg complex, but degradation within the SK moiety to give a 37000-Mr fragment and conversion of the Glu-plasminogen into Lys-plasmin are known to occur very rapidly in plasma (Brockway & Castellino, 1974; Markus et al., 1976) . The active species throughout most of the period of fibrinolysis is likely to have been the streptokinase (37000-Mr)^Lys-plasmin complex. It was therefore of interest to examine the effect of stabilizing the structure of the native streptokinase plasminogen complex by active-centre acylation. In addition, the use of inactive precursors of the fibrinolytic enzymes decreases the extent of proteolytic modification of fibrin before the lysis rate is measured and permits a better equilibration of plasminogen activator and fibrin. In order to make valid comparisons between the different activator classes, it was essential to use acyl-enzymes with equivalent deacylation rates. It was necessary to use slightly different conditions for determining the deacylation rates of acyl-enzymes derived from t-PA and u-PA on the one hand and SK Plg on the other. The former were deacylated in a phosphate buffer (Table 2 ), but the deacylation products of acyl-plasminogen * streptokinase complexes were found to be unstable in this buffer system at 37 'C. In order to obtain accurate deacylation rate constants for these complexes from activityregeneration measurements, it was necessary to use a buffer containing 20 % (v/v) glycerol. At this concentration, glycerol was found to increase the deacylation rate constants of t-PA and u-PA derivatives approximately 3-fold when compared with rates in phosphate buffer. Radiochemical determination of the deacylation of 4-anisoyl-plasminogen streptokinase complex (BRL 26921) in human plasma with the use of a tritiated 4-anisoyl function confirmed that a correction factor of this magnitude needed to be applied to measurements in glycerol-containing buffer (M. J. Hibbs, unpublished work). Therefore the relevant stability of BRL 26921 lies between that of the heterobifunctional acyl-enzyme PDAEB-t-PA (half-life for deacylation 63 min) and that of 4-NN-dimethylaminobenzoyl-t-PA (t1 240 min) and is similar to that of 4-aminobenzoyl-u-1A (t1 140 min). 4-Guanidinobenzoyl-plasminogen * streptokinase was similar in stability to 4-aminobenzoyl-t-PA.
The above comparisons indicated ( Table 2 ) that the potencies of acyl-plasminogen -streptokinase complexes were similar to those ofacyl-t-PAs ofcomparable stability and that comparable derivatives of both enzymes were at least 5-fold more potent than derivatives of two-chain u-PA. The relationship between the potency ([E]50%') and the deacylation rate constant (corrected for solvent effects) is shown in Fig. 3 . It is noteworthy that fibrinolytic activity was demonstrable with very slowly deacylating derivatives of t-PA and SK Plg but was much less marked with similar derivatives of u-PA. This phenomenon may be explained by high-affinity fibrin binding of the first two classes of plasminogen activator followed by suffi-cient deacylation during the period of incubation of the clot in plasma to generate a small amount of fibrin-bound active enzyme, which rapidly activated a much larger amount of fibrin-bound plasminogen. In consistent with the values of Km for plasminogen in the presence of fibrin that were obtained from plasminogen activation kinetics. The present study suggests that, provided that it is presented to fibrin in an undegraded form, streptokinase-plasminogen complex can display an affinity for fibrin that is not only significantly greater than that shown by plasminogen forms or two-chain urokinase but which is also comparable with that of t-PA. This conclusion contrasts with the widely held view that streptokinase -plasminogen does not bind specifically to fibrin (Collen & Verstraete, 1983; Fox et al., 1984) . That conclusion derived partly from the structural resemblance of the complex to the weakly binding plasminogen and partly from clinical experience with streptokinase itself. Our results suggest that, in agreement with the conclusions of Cederholm-Williams (1981) , the binding of streptokinase to plasminogen confers substantial extra fibrin affinity upon the latter protein. The precise structural basis for an increase in binding energy to the level apparently similar to that provided by the 'kringle' and 'finger' domains of t-PA (Pennica et al., 1983; Banyai et al., 1983 ) is unknown. An interaction between the streptokinase moiety and fibrin-bound plasminogen or a streptokinase-induced conformation change in the plasminogen kringles are both plausible hypotheses.
In clinical use, streptokinase probably undergoes rapid internal proteolytic degradation (Markus et al., 1976) , and the activator complex is also inactivated and removed from the circulation by plasma proteinase inhibitors, particularly ac2-macroglobulin (Gonias et al., 1982) . All of these processes may be delayed by the provision of the complex in an undegraded pro-drug form. The data presented here suggest that improved fibrin affinity contributes to the potency and hence to the emerging clinical usefulness of BRL 26921 (Been et al., 1985) . We 
